Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-blind, Placebo-controlled, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)

NCT05764239 is registered in ClinicalTrials.gov with Synlogic as lead sponsor.

NCT NCT05764239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05764239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-blind, Placebo-controlled, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)
Lead sponsor
Synlogic
Phase
Phase 3
Overall status
Terminated
Start date
July 5, 2023
Completion date
March 15, 2024
Enrollment
35 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

phenylketonuria